Monaco Asset Management SAM Takes $338,000 Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Monaco Asset Management SAM bought a new stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 734,148 shares of the biopharmaceutical company’s stock, valued at approximately $338,000. Monaco Asset Management SAM owned about 0.20% of Lexicon Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Point72 Asset Management L.P. raised its stake in Lexicon Pharmaceuticals by 630.7% during the 4th quarter. Point72 Asset Management L.P. now owns 8,988,421 shares of the biopharmaceutical company’s stock valued at $6,638,000 after acquiring an additional 7,758,371 shares during the last quarter. Schonfeld Strategic Advisors LLC raised its stake in Lexicon Pharmaceuticals by 301.5% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 7,558,621 shares of the biopharmaceutical company’s stock valued at $5,582,000 after acquiring an additional 5,676,021 shares during the last quarter. Nantahala Capital Management LLC raised its stake in Lexicon Pharmaceuticals by 186.6% during the 4th quarter. Nantahala Capital Management LLC now owns 6,604,150 shares of the biopharmaceutical company’s stock valued at $4,877,000 after acquiring an additional 4,300,000 shares during the last quarter. Northern Trust Corp raised its stake in Lexicon Pharmaceuticals by 14.4% during the 4th quarter. Northern Trust Corp now owns 1,308,651 shares of the biopharmaceutical company’s stock valued at $966,000 after acquiring an additional 164,620 shares during the last quarter. Finally, Tang Capital Management LLC raised its stake in Lexicon Pharmaceuticals by 750.3% during the 4th quarter. Tang Capital Management LLC now owns 850,268 shares of the biopharmaceutical company’s stock valued at $628,000 after acquiring an additional 750,268 shares during the last quarter. 74.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on LXRX shares. Wall Street Zen started coverage on Lexicon Pharmaceuticals in a research note on Monday, April 21st. They set a “sell” rating for the company. HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of Lexicon Pharmaceuticals in a research report on Tuesday, June 24th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $3.67.

Lexicon Pharmaceuticals Stock Performance

NASDAQ LXRX opened at $1.07 on Wednesday. The company has a current ratio of 2.22, a quick ratio of 2.22 and a debt-to-equity ratio of 0.48. The business’s 50 day moving average is $0.88 and its two-hundred day moving average is $0.70. Lexicon Pharmaceuticals, Inc. has a 12-month low of $0.28 and a 12-month high of $2.39. The stock has a market capitalization of $386.80 million, a price-to-earnings ratio of -2.10 and a beta of 1.13.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.03. Lexicon Pharmaceuticals had a negative return on equity of 103.16% and a negative net margin of 568.04%. The company had revenue of $1.26 million for the quarter, compared to analysts’ expectations of $1.26 million. Research analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.66 EPS for the current year.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.